| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | EIF3; eIF3 theta; eIF3a; EIF3S10; P167; p180; p185; TIF32;;eIF3A |
| WB Predicted band size | Calculated MW: 167 kDa ; Observed MW: 160 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human eIF3A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于eIF3A抗体的3篇参考文献的简要信息(示例性质，非真实文献)：
1. **文献名称**：*eIF3A promotes lung cancer progression by regulating cell cycle via p27 modulation*
**作者**：Zhang Y, et al.
**摘要**：研究通过eIF3A抗体检测非小细胞肺癌组织中eIF3A的异常高表达，发现其通过下调p27蛋白促进细胞周期进程，提示eIF3A作为肺癌治疗的潜在靶点。
2. **文献名称**：*The role of eIF3A in cisplatin resistance: Insights from translational control mechanisms*
**作者**：Wang L, et al.
**摘要**：利用eIF3A抗体进行蛋白质互作实验，发现eIF3A通过选择性调控DNA修复相关mRNA的翻译，增强卵巢癌细胞对顺铂的耐药性，为克服化疗耐药提供新方向。
3. **文献名称**：*eIF3A interacts with mTOR signaling pathway to regulate cellular senescence*
**作者**：Kim S, et al.
**摘要**：通过免疫共沉淀(使用eIF3A抗体)和功能实验，揭示eIF3A与mTOR复合物相互作用，调控衰老相关蛋白表达，影响细胞衰老进程。
注：以上内容为模拟示例，实际文献需通过数据库(如PubMed)检索确认。
The eukaryotic translation initiation factor 3 subunit A (eIF3A) is a critical component of the eIF3 complex, the largest multiprotein assembly involved in initiating cap-dependent translation in eukaryotes. eIF3A, also known as eIF3-p170. plays a central role in ribosome recruitment to mRNA, scanning for the start codon, and stabilizing interactions between the 40S ribosomal subunit and other initiation factors. Structurally, it contains conserved PCI (Proteasome, COP9. eIF3) and RNA recognition motif (RRM) domains, enabling interactions with ribosomes and regulatory RNAs. Dysregulation of eIF3A has been implicated in cancers, including breast, lung, and ovarian cancers, where its overexpression often correlates with poor prognosis, tumor proliferation, and drug resistance.
Antibodies targeting eIF3A are essential tools for studying its expression, localization, and functional roles. They are widely used in techniques such as Western blotting, immunofluorescence, and immunohistochemistry to investigate eIF3A's involvement in translational control and disease mechanisms. Commercially available eIF3A antibodies are typically raised against specific epitopes within its N-terminal or C-terminal regions and validated for specificity across human, mouse, and rat models. Recent studies also utilize these antibodies to explore eIF3A's non-canonical roles, including its interaction with viral RNAs and stress granule dynamics. However, variability in antibody performance across experimental conditions underscores the need for rigorous validation to ensure reproducibility in translational research.
×
